
Survival has become the gold standard for determining the relative effectiveness of chemotherapy regimens in phase III clinical trials and is measured generally as the median zzso Response could be a surrogate for survival in evaluating clinical trials for chemotherapy, but it has become a controversial measurement zzso because of the quantitative zzso in measurement and the fact that differences in response rates are not commonly translated into differences in zzso However, if response is indeed a zzso of survival, the median survival (the point at which 50% of the patients are zzso will not be impacted because response rates zzso for most advanced zzso are less than zzso Nonetheless, a survival benefit has been identified for tumors in which response rates are 50% or less in 4 phase III zzso zzso 2 in breast cancer (a high zzso zzso also show significant differences in zzso These data would imply that factors other than tumor response could be operative in influencing zzso It is a zzso truth that zzso live longer than zzso but the response and survival relationship is complex and both parameters are important in clinical zzso 

